Running Title: Inebilizumab pharmacodynamic modeling and
exposure-response assessment
Li Yan1*, Bing Wang2, Dewei
She1, Ben Mitchel2, Ryan
Criste2, Daniel Cimbora1, Eliezer
Katz1 and William A Rees1
1Horizon Therapeutics, Gaithersburg, MD, USA;2Amador Bioscience, Pleasanton, CA, USA